Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSIW) Total Non-Current Liabilities (2022 - 2025)

TriSalus Life Sciences' Total Non-Current Liabilities history spans 4 years, with the latest figure at $59.0 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 39.05% year-over-year to $59.0 million; the TTM value through Dec 2025 reached $59.0 million, up 39.05%, while the annual FY2025 figure was $59.0 million, 39.05% up from the prior year.
  • Total Non-Current Liabilities reached $59.0 million in Q4 2025 per TLSIW's latest filing, up from $58.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $59.0 million in Q4 2025 to a low of $19.6 million in Q3 2023.
  • Average Total Non-Current Liabilities over 4 years is $43.7 million, with a median of $42.5 million recorded in 2024.
  • Peak YoY movement for Total Non-Current Liabilities: grew 1.81% in 2023, then surged 110.42% in 2024.
  • A 4-year view of Total Non-Current Liabilities shows it stood at $33.9 million in 2022, then grew by 1.81% to $34.6 million in 2023, then increased by 22.86% to $42.5 million in 2024, then surged by 39.05% to $59.0 million in 2025.
  • Per Business Quant, the three most recent readings for TLSIW's Total Non-Current Liabilities are $59.0 million (Q4 2025), $58.2 million (Q3 2025), and $50.7 million (Q2 2025).